You are here

  • Home
  • Archive
  • Volume 76, Issue 8
  • A nationwide non-medical switch from originator infliximab to biosimilar CT-P13 in 802 patients with inflammatory arthritis: 1-year clinical outcomes from the DANBIO registry

Citation Tools

Article menu
Download PDFPDF
Clinical and epidemiological research
Concise report
A nationwide non-medical switch from originator infliximab to biosimilar CT-P13 in 802 patients with inflammatory arthritis: 1-year clinical outcomes from the DANBIO registry

Download to a citation manager

Download the citation for this article by clicking on one of the following citation managers:

Cite this article as:
Glintborg B, Sørensen IJ, Loft AG On behalf of all departments of rheumatology in Denmark, et al
A nationwide non-medical switch from originator infliximab to biosimilar CT-P13 in 802 patients with inflammatory arthritis: 1-year clinical outcomes from the DANBIO registry
Annals of the Rheumatic Diseases 2017;76:1426-1431.